Expanding treatment options for cancer patients.

Celcuity diagnoses cancer drivers molecular tests cannot detect to identify new treatment options for patients.

Learn About CELsignia Tests
Clinical Trials

Cancer patients need more options.

  • Genomic testing cannot identify the driver of all patients’ cancer.
  • Without knowing the driver, doctors cannot prescribe many targeted therapies.
  • CELsignia fills this void by measuring complex cellular activities genomic tests cannot detect.
  • Patients whose cancer driver is diagnosed by CELsignia have more treatment options.